Business Context and Reporting Period
Company: NanoViricides, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: September 16, 2010 (Event Date)
Reporting Period: Specific event reporting regarding a follow-on equity offering and subsequent closing on September 21, 2010.
Key Financial Metrics
This filing reports on a specific capital raise event rather than a full period of operations. Key financial figures include:
- Gross Proceeds Raised: $2,500,000 (from the First Follow-on Closing on September 21, 2010).
- Estimated Offering Expenses: Approximately $270,000 (including placement agent and attorneys' fees).
- Placement Agent Fee: 8% of the gross purchase price paid to Midtown Partners & Co., LLC.
- Shares Issued (First Closing): 250,000 shares of Series B Convertible Preferred Stock.
- Purchase Price: $10.00 per share of Series B Preferred Stock.
- Conversion Price (First Closing): $0.93007 per share of Common Stock.
Note: The filing does not provide data on total revenue, net profit, operating cash flow, overall debt levels, or liquidity ratios for the company.
Material Changes and Transaction Details
The company entered into a Letter Agreement and Amendment with Seaside 88, LP to modify a May 11, 2010 Securities Purchase Agreement. Material changes include:
- Transaction Structure: The purchase of an additional 500,000 shares of Series B Convertible Preferred Stock was split into two closings of 250,000 shares each.
- Timing: The second closing is scheduled for 90 days after the first closing (September 21, 2010).
- Conversion Terms Adjustment: The number of shares automatically converting from Series B Preferred to Common Stock was reduced from 60,000 to 40,000 shares per conversion date, commencing on the First Follow-on Closing Date and every 14th day thereafter.
- Conversion Formula: Conversion is based on a discount to the Volume Weighted Average Price (VWAP), specifically the lower of 85% of the 10-day VWAP or 88% of the prior day's VWAP.
- Price Floor: Conversions will not occur if the 20-Day VWAP is below $0.20; unconverted shares roll over to the next date.
Outlook, Risks, and Management Commentary
The filing contains forward-looking statements regarding anticipated subsequent conversions. Management highlights the following risks and contingencies:
- Closing Conditions: Uncertainty regarding the ability to satisfy conditions for subsequent closings on a timely basis or at all.
- Dilution: Substantial dilution to current stockholders due to the purchase price discount offered to Seaside 88, LP.
- Market Overhang: Potential market overhang resulting from the resale of common stock by Seaside 88, LP upon conversion of the Series B Preferred Stock.
- Regulatory Status: The offering is made pursuant to a shelf registration statement on Form S-3 (File No. 333-165221) declared effective on April 29, 2010.
Investor Verification Checklist
- Verify the exact date and terms of the second closing (scheduled 90 days post-September 21, 2010).
- Confirm the actual net proceeds after deducting the full $270,000 in estimated expenses.
- Monitor the 20-Day VWAP to determine if the $0.20 "Floor" prevents future automatic conversions.
- Review the full text of the Letter Agreement (Exhibit 10.1) for limitations on the conversion schedule.
- Assess the potential dilution impact on existing common shareholders based on the $0.93007 conversion price.